Skip to main content
. Author manuscript; available in PMC: 2018 Jan 9.
Published in final edited form as: Cancer Cell. 2017 Jan 9;31(1):50–63. doi: 10.1016/j.ccell.2016.12.002

Figure 7. Genetic and pharmacological inhibition of SETD8 impairs tumor growth and prolongs murine survival in in vivo model of NB.

Figure 7

(A) SY5Y (left) and NGP (right) cells were treated ex-vivo for 24 hr with 2 μM UNC0379, SETD8 inhibitor, and then injected into nude mice. Day 0 indicates the day of cell implantation. Immunoblot of proteins from 2 tumors randomly chosen from each group (untreated and ex-vivo UNC0379 treated) collected 20 days after the injection and blotted with antibodies to SETD8, p53K382me1, p53 and GAPDH (insets). Bars show the tumor size average of 15 mice/group ± SEM. Slopes of the growth rate were compared by t test.

(B) Kaplan-Meier graphs showing the murine survival upon ex-vivo treatment of SY5Y (left) and NGP (right) with UNC0379. The statistical significance between 2 treatment groups was evaluated using a log-rank test.

(C) SY5Y-NB (left) and NGP-NB (right) xenograft tumor size in mice treated with doxycycline (DOXY) after tumors reached 75-100 mm3. Day 0 indicates the day of cell implantation. After 9 days, mice were divided in 2 groups: untreated and doxy-treated. Immunoblot of proteins from 2 tumors randomly chosen from each group 20 days after the injection and blotted with antibodies to SETD8, p53K382me1, p53 and GAPDH (insets). Bars show the tumor size average of 15 mice/group ± SEM. Slopes of the growth rate were compared by t test.

(D) Kaplan-Meier graphs showing the murine survival upon SETD8 silencing in SY5Y-NB (left) and NGP-NB (right) tumor bearing mice. The statistical significance between 2 treatment groups was evaluated using a log-rank test.

See also Figure S7.